AU2001255398A1 - Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor - Google Patents

Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor

Info

Publication number
AU2001255398A1
AU2001255398A1 AU2001255398A AU5539801A AU2001255398A1 AU 2001255398 A1 AU2001255398 A1 AU 2001255398A1 AU 2001255398 A AU2001255398 A AU 2001255398A AU 5539801 A AU5539801 A AU 5539801A AU 2001255398 A1 AU2001255398 A1 AU 2001255398A1
Authority
AU
Australia
Prior art keywords
ctla
antibodies
bind
antigen binding
binding portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255398A
Inventor
Jeffrey A Bluestone
Mary Collins
Matthew Griffin
David Kranz
Matthew Whitters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
University of Illinois
Original Assignee
Genetics Institute LLC
University of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC, University of Illinois filed Critical Genetics Institute LLC
Publication of AU2001255398A1 publication Critical patent/AU2001255398A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001255398A 2000-04-12 2001-04-12 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor Abandoned AU2001255398A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19685100P 2000-04-12 2000-04-12
US60/196,851 2000-04-12
PCT/US2001/012275 WO2001079300A1 (en) 2000-04-12 2001-04-12 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor

Publications (1)

Publication Number Publication Date
AU2001255398A1 true AU2001255398A1 (en) 2001-10-30

Family

ID=22727032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255398A Abandoned AU2001255398A1 (en) 2000-04-12 2001-04-12 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor

Country Status (4)

Country Link
US (1) US20030086932A1 (en)
EP (1) EP1274733A1 (en)
AU (1) AU2001255398A1 (en)
WO (1) WO2001079300A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070153A1 (en) * 2008-08-13 2011-03-24 Searete, Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
SI3303394T1 (en) 2015-05-29 2020-10-30 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
SG10201912560YA (en) 2016-12-07 2020-02-27 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
FR2695563B1 (en) * 1992-09-11 1994-12-02 Pasteur Institut Microparticles carrying antigens and their use for the induction of humoral or cellular responses.
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression

Also Published As

Publication number Publication date
WO2001079300A9 (en) 2002-12-27
EP1274733A1 (en) 2003-01-15
WO2001079300A1 (en) 2001-10-25
US20030086932A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
AU2001264946A1 (en) Bispecific immunoglobulin-like antigen binding proteins and method of production
AU2002327704A1 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
AU2002220843A1 (en) Humanised antibodies and uses thereof
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
AU4643596A (en) Chimeric antibodies comprising antigen binding sites and b and t cell epitopes
AU2559799A (en) Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
AU3041100A (en) Binding of antibody fragments to solid supports
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
AU2001255398A1 (en) Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
EP1581096A4 (en) Antigen pipa and antibodies that bind thereto
AU2003234706A1 (en) Antibodies that specifically bind to tl5
AU2003218456A1 (en) Antibodies that specifically bind to gmad
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU1190101A (en) Engineering antibodies that bind irreversibly
AU2003275834A1 (en) ANTIBODIES THAT BIND alphaE INTEGRIN
HUP0001808A3 (en) Antibodies that bind to the nidogen-binding domain of laminin, their production and use
WO2003061561A9 (en) Epsilon immunoglobulin chain derived peptides for induction of anti-ige antibodies
AU6068000A (en) Peptide ligands that bind igm antibodies and block interaction with antigen
AU2001249546A1 (en) Methods for treating disease with antibodies to cxcr3
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
EP0889734A4 (en) Monoclonal antibodies which bind to tumor rejection antigen precursor melan-a, and uses thereof
WO1999028465A3 (en) Pias molecules that recognize and bind stat proteins and uses thereof
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens